Ascendis Pharma Files 6-K Report

Ticker: ASND · Form: 6-K · Filed: May 14, 2025 · CIK: 1612042

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, reporting-obligation

Related Tickers: ASND

TL;DR

Ascendis Pharma (ASND) filed a 6-K, confirming its foreign private issuer status and 20-F reporting.

AI Summary

Ascendis Pharma A/S filed a Form 6-K on May 14, 2025, to report its activities as a foreign private issuer. The filing indicates that the company is subject to the reporting requirements of the Securities Exchange Act of 1934 and will file annual reports under Form 20-F. The report includes information about the company's principal executive offices located in Hellerup, Denmark.

Why It Matters

This filing provides routine updates for investors and regulators regarding Ascendis Pharma's status as a foreign private issuer and its ongoing reporting obligations.

Risk Assessment

Risk Level: low — This is a routine administrative filing for a foreign private issuer and does not contain material non-public information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the registrant makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.

What is Ascendis Pharma A/S's filing status?

Ascendis Pharma A/S is a foreign private issuer and files its annual reports under Form 20-F.

Where are Ascendis Pharma A/S's principal executive offices located?

Ascendis Pharma A/S's principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.

What is the filing date of this Form 6-K?

This Form 6-K was filed as of May 14, 2025.

What is the SEC file number for Ascendis Pharma A/S?

The SEC file number for Ascendis Pharma A/S is 001-36815.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 14, 2025 regarding Ascendis Pharma A/S (ASND).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing